Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Retained Earnings (2018 - 2025)

Bicycle Therapeutics' Retained Earnings history spans 8 years, with the latest figure at -$899.8 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 756193.28% year-over-year to -$899.8 million; the TTM value through Dec 2025 reached -$899.8 million, down 756193.28%, while the annual FY2025 figure was -$899.8 million, 756193.28% down from the prior year.
  • Retained Earnings reached -$899.8 million in Q4 2025 per BCYC's latest filing, down from -$3.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $387000.0 in Q4 2022 to a low of -$899.8 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$243.3 million, with a median of -$209.4 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: soared 109.13% in 2024, then crashed 756193.28% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$218.4 million in 2021, then skyrocketed by 100.18% to $387000.0 in 2022, then crashed by 436.95% to -$1.3 million in 2023, then skyrocketed by 109.13% to $119000.0 in 2024, then plummeted by 756193.28% to -$899.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Retained Earnings are -$899.8 million (Q4 2025), -$3.5 million (Q3 2025), and -$3.4 million (Q2 2025).